Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
Provided By PR Newswire
Last update: Oct 24, 2025
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials
Read more at prnewswire.com906.86
+10.33 (+1.15%)
102.92
+1.35 (+1.33%)
Find more stocks in the Stock Screener
LLY Latest News and Analysis
2 days ago - By: Chartmill
6 days ago - By: Chartmill
8 days ago - By: Chartmill
